NASDAQ:SYNH - Syneos Health Stock Price, Price Target & More

$37.90 -0.30 (-0.79 %)
(As of 04/24/2018 01:54 PM ET)
Previous Close$38.20
Today's Range$37.85 - $39.35
52-Week Range$31.10 - $61.10
Volume255,247 shs
Average Volume992,654 shs
Market Capitalization$3.92 billion
P/E Ratio19.59
Dividend YieldN/A
Beta0.8

About Syneos Health (NASDAQ:SYNH)

Syneos Health logoSyneos Health, Inc. operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Raleigh, North Carolina.

Receive SYNH News and Ratings via Email

Sign-up to receive the latest news and ratings for SYNH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SYNH
CUSIPN/A
Phone919-876-9300

Debt

Debt-to-Equity Ratio0.98%
Current Ratio1.23%
Quick Ratio1.23%

Price-To-Earnings

Trailing P/E Ratio19.59
Forward P/E Ratio16.62
P/E Growth0.95

Sales & Book Value

Annual Sales$2.67 billion
Price / Sales1.47
Cash Flow$3.7938 per share
Price / Cash9.99
Book Value$28.97 per share
Price / Book1.31

Profitability

EPS (Most Recent Fiscal Year)$1.94
Net Income$-138,460,000.00
Net Margins-5.18%
Return on Equity10.78%
Return on Assets4.22%

Miscellaneous

Employees21,000
Outstanding Shares103,800,000

How to Become a New Pot Stock Millionaire

Syneos Health (NASDAQ:SYNH) Frequently Asked Questions

What is Syneos Health's stock symbol?

Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."

How were Syneos Health's earnings last quarter?

Syneos Health (NASDAQ:SYNH) issued its quarterly earnings results on Wednesday, February, 28th. The company reported $0.67 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.52 by $0.15. The business had revenue of $750.47 million for the quarter, compared to analyst estimates of $757.94 million. Syneos Health had a positive return on equity of 10.78% and a negative net margin of 5.18%. View Syneos Health's Earnings History.

What guidance has Syneos Health issued on next quarter's earnings?

Syneos Health issued an update on its FY18 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of $2.68-2.94 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.56. The company issued revenue guidance of $3.23-3.33 billion, compared to the consensus revenue estimate of $3.21 billion.Syneos Health also updated its Q1 guidance to $0.54-0.60 EPS.

What price target have analysts set for SYNH?

11 analysts have issued 12-month price targets for Syneos Health's stock. Their predictions range from $41.00 to $65.00. On average, they expect Syneos Health's stock price to reach $50.7778 in the next twelve months. View Analyst Ratings for Syneos Health.

Who are some of Syneos Health's key competitors?

Who are Syneos Health's key executives?

Syneos Health's management team includes the folowing people:
  • Mr. Alistair MacDonald, CEO & Director (Age 48)
  • Dr. Michael Gibertini Ph.D., Pres of Clinical Devel. for Therapeutic Bus. Units (Age 60)
  • Mr. Jason M. Meggs, Exec. VP, Interim CFO & Principal Accounting Officer (Age 42)
  • Dr. Judith Ng-Cashin, Chief Scientific Officer
  • Ms. Rachel Stahler, Chief Information Officer (Age 42)

Has Syneos Health been receiving favorable news coverage?

Media coverage about SYNH stock has been trending somewhat positive on Tuesday, Accern Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Syneos Health earned a media sentiment score of 0.03 on Accern's scale. They also gave news stories about the company an impact score of 46.08 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

How do I buy shares of Syneos Health?

Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Syneos Health's stock price today?

One share of SYNH stock can currently be purchased for approximately $37.90.

How big of a company is Syneos Health?

Syneos Health has a market capitalization of $3.92 billion and generates $2.67 billion in revenue each year. The company earns $-138,460,000.00 in net income (profit) each year or $1.94 on an earnings per share basis. Syneos Health employs 21,000 workers across the globe.

How can I contact Syneos Health?

Syneos Health's mailing address is 3201 Beechleaf Court Suite 600, Raleigh NC, 27604. The company can be reached via phone at 919-876-9300 or via email at [email protected]


MarketBeat Community Rating for Syneos Health (SYNH)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  264 (Vote Outperform)
Underperform Votes:  176 (Vote Underperform)
Total Votes:  440
MarketBeat's community ratings are surveys of what our community members think about Syneos Health and other stocks. Vote "Outperform" if you believe SYNH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYNH will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Syneos Health (NASDAQ:SYNH) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
11 Wall Street analysts have issued ratings and price targets for Syneos Health in the last 12 months. Their average twelve-month price target is $50.7778, suggesting that the stock has a possible upside of 33.98%. The high price target for SYNH is $65.00 and the low price target for SYNH is $41.00. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.732.702.602.60
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $50.7778$50.8750$49.8750$65.00
Price Target Upside: 33.98% upside21.42% upside20.76% upside18.29% upside

Syneos Health (NASDAQ:SYNH) Consensus Price Target History

Price Target History for Syneos Health (NASDAQ:SYNH)

Syneos Health (NASDAQ:SYNH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/20/2018Mitsubishi UFJ Financial GroupInitiated CoverageOverweight$50.00LowView Rating Details
3/1/2018BarclaysReiterated RatingEqual Weight -> Equal Weight$40.00 -> $43.00LowView Rating Details
3/1/2018SunTrust BanksBoost Price TargetBuy$55.00LowView Rating Details
2/26/2018KeyCorpReiterated RatingOverweight -> Overweight$50.00 -> $46.00LowView Rating Details
2/23/2018Wells FargoUpgradeMarket Perform -> OutperformHighView Rating Details
2/22/2018Robert W. BairdSet Price TargetBuy$50.00HighView Rating Details
1/4/2018Credit Suisse GroupReiterated RatingBuy$52.00MediumView Rating Details
12/1/2017MizuhoSet Price TargetNeutral -> Neutral$57.00 -> $41.00MediumView Rating Details
11/10/2017Jefferies GroupReiterated RatingBuy$55.00N/AView Rating Details
8/7/2017Goldman SachsReiterated RatingBuy -> Buy$65.00LowView Rating Details
6/20/2017William BlairDowngradeOutperform -> Market PerformHighView Rating Details
12/19/2016First AnalysisInitiated CoverageEqual -> Equal Weight$59.00N/AView Rating Details
(Data available from 4/24/2016 forward)

Earnings

Syneos Health (NASDAQ:SYNH) Earnings History and Estimates Chart

Earnings by Quarter for Syneos Health (NASDAQ:SYNH)

Syneos Health (NASDAQ:SYNH) Earnings Estimates

Current Year EPS Consensus Estimate: $2.28 EPS
Next Year EPS Consensus Estimate: $2.63 EPS

Syneos Health (NASDAQ SYNH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2018Q4 2017$0.52$0.67$757.94 million$750.47 millionViewN/AView Earnings Details
11/9/2017Q3 2017$0.63$0.54$604.95 million$592.21 millionViewN/AView Earnings Details
7/27/2017Q2 2017$0.64$0.64$256.76 million$258.10 millionViewN/AView Earnings Details
5/10/2017Q1 2017$0.55$0.60$250.76 million$252.10 millionViewN/AView Earnings Details
2/28/2017Q4 2016$0.67$0.67$269.00 million$263.00 millionViewListenView Earnings Details
10/31/2016Q316$0.59$0.64$259.89 million$259.56 millionViewListenView Earnings Details
7/27/2016Q216$0.58$0.61$252.39 million$258.80 millionViewListenView Earnings Details
5/2/2016Q116$0.53$0.58$237.78 million$249.00 millionViewListenView Earnings Details
2/25/2016Q415$0.49$0.54$239.31 million$241.40 millionViewListenView Earnings Details
10/29/2015Q3$0.44$0.58$230.60 million$234.50 millionViewListenView Earnings Details
7/30/2015Q215$0.34$0.47$219.08 million$227.40 millionViewListenView Earnings Details
4/27/2015Q115$0.26$0.41$211.20 million$308.90 millionViewListenView Earnings Details
2/24/2015Q414$0.21$0.24$207.88 million$213.70 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Syneos Health (NASDAQ:SYNH) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Syneos Health (NASDAQ SYNH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.57%
Insider Trading History for Syneos Health (NASDAQ:SYNH)

Syneos Health (NASDAQ SYNH) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/22/2018Christopher L GaenzleCAOSell1,470$41.00$60,270.00View SEC Filing  
9/18/2017Alistair MacdonaldCEOSell2,348$54.60$128,200.8099,453View SEC Filing  
9/18/2017Christopher L GaenzleCAOSell4,682$54.56$255,449.9260,579View SEC Filing  
9/18/2017Gregory S RushCFOSell9,703$54.48$528,619.4478,593View SEC Filing  
9/1/2017Christopher L GaenzleCAOSell42,601$58.67$2,499,400.6769,557View SEC Filing  
9/1/2017Gregory S RushCFOSell88,739$58.99$5,234,713.61149,301View SEC Filing  
8/30/2017Gregory S RushCFOSell41,420$58.26$2,413,129.2042,793View SEC Filing  
8/17/2017Alistair MacdonaldCEOSell8,828$55.65$491,278.20110,629View SEC Filing  
7/3/2017Alistair MacdonaldCEOSell10,555$58.38$616,200.9083,935View SEC Filing  
6/30/2017Christopher L GaenzleCAOSell6,873$58.32$400,833.3647,450View SEC Filing  
5/1/2017Alistair MacdonaldCEOSell9,467$45.00$426,015.0083,935View SEC Filing  
4/3/2017Christopher L GaenzleCAOSell4,733$45.70$216,298.1053,050View SEC Filing  
3/3/2017Alistair MacdonaldCEOSell8,828$45.00$397,260.0083,296View SEC Filing  
1/20/2017Alistair MacdonaldCEOSell1,375$50.50$69,437.5052,854View SEC Filing  
1/20/2017Christopher L GaenzleCAOSell1,186$50.09$59,406.7440,223View SEC Filing  
1/19/2017Gregory S RushVPSell2,907$50.57$147,006.9945,782View SEC Filing  
1/5/2017Alistair MacdonaldCEOSell14,840$52.19$774,499.6069,069View SEC Filing  
9/30/2016Gregory S RushVPSell35,503$44.70$1,586,984.1082,712View SEC Filing  
9/27/2016D. Jamie MacdonaldCEOSell53,970$44.30$2,390,871.0062,220View SEC Filing  
9/26/2016Robert W BreckonDirectorSell12,197$44.16$538,619.5215,561View SEC Filing  
9/19/2016David F BurgstahlerDirectorBuy1,000$43.19$43,190.0036,065View SEC Filing  
9/14/2016Christopher L GaenzleCAOSell4,734$43.14$204,224.7619,252View SEC Filing  
8/17/2016Alistair MacdonaldCOOSell8,828$43.80$386,666.4063,057View SEC Filing  
8/4/2016Avista Capital Partners Ii Gp,Major ShareholderSell2,554,409$42.06$107,438,442.54View SEC Filing  
8/4/2016Teachers Pension Plan OntarioDirectorSell2,445,591$42.06$102,861,557.46View SEC Filing  
8/2/2016D. Jamie MacdonaldCEOSell31,279$43.00$1,344,997.00107,488View SEC Filing  
8/1/2016Robert W BreckonDirectorSell108$42.00$4,536.007,961View SEC Filing  
7/28/2016Gregory S RushVPSell4,066$45.23$183,905.1822,165View SEC Filing  
7/20/2016D. Jamie MacdonaldCEOSell100,593$43.00$4,325,499.00105,795View SEC Filing  
7/15/2016Gregory S RushCFOSell5,917$41.50$245,555.5024,016View SEC Filing  
7/11/2016Alistair MacdonaldCOOSell9,468$40.19$380,518.9228,144View SEC Filing  
7/11/2016Christopher L GaenzleCAOSell21,918$40.20$881,103.6033,530View SEC Filing  
7/1/2016Gregory S RushCFOSell1,358$37.97$51,563.2619,457View SEC Filing  
7/1/2016Robert W BreckonDirectorSell421$37.97$15,985.378,069View SEC Filing  
6/15/2016Christopher L GaenzleCAOSell7,702$40.14$309,158.2818,287View SEC Filing  
6/6/2016Michael GibertiniInsiderSell213,966$43.11$9,224,074.26200,998View SEC Filing  
6/2/2016Robert W BreckonDirectorSell11,691$43.53$508,909.2319,710View SEC Filing  
5/6/2016Avista Capital Partners Ii Gp,Major ShareholderSell4,087,054$45.12$184,407,876.48View SEC Filing  
5/6/2016Teachers Pension Plan OntarioDirectorSell3,912,946$45.12$176,552,123.52View SEC Filing  
4/18/2016James T OgleDirectorSell114,806$50.00$5,740,300.00293,192View SEC Filing  
4/12/2016D. Jamie MacdonaldCEOSell94,675$48.00$4,544,400.00138,398View SEC Filing  
4/1/2016Michael GibertiniInsiderSell9,000$40.78$367,020.0056,282View SEC Filing  
3/1/2016Michael GibertiniInsiderSell9,000$39.85$358,650.0056,282View SEC Filing  
2/4/2016Robert W. BreckonDirectorSell3,882$40.03$155,396.468,432View SEC Filing  
2/1/2016Gregory S. RushCFOSell17,752$40.27$714,873.0420,132View SEC Filing  
2/1/2016Michael GibertiniinsiderSell9,000$40.57$365,130.0047,282View SEC Filing  
1/4/2016Michael GibertiniinsiderSell9,000$46.83$421,470.0036,282View SEC Filing  
12/31/2015Alistair MacdonaldCOOSell159,599$47.46$7,574,568.548,699View SEC Filing  
12/31/2015Christopher L. GaenzleCAOSell9,468$48.18$456,168.247,291View SEC Filing  
12/31/2015Gregory S. RushCFOSell35,503$48.17$1,710,179.518,132View SEC Filing  
12/29/2015James T. OgleDirectorSell9,717$50.06$486,433.02183,386View SEC Filing  
12/8/2015Christopher L. GaenzleCAOSell25,185$41.78$1,052,229.307,291View SEC Filing  
12/8/2015Gregory S. RushCFOSell81,035$45.13$3,657,109.558,132View SEC Filing  
12/7/2015Alistair MacdonaldCOOSell42,959$44.63$1,917,260.1755,681View SEC Filing  
12/7/2015Avista Capital Partners Ii Gp,Major ShareholderSell4,597,937$45.00$206,907,165.00View SEC Filing  
12/7/2015Teachers Pension Plan OntarioDirectorSell4,402,063$45.00$198,092,835.00View SEC Filing  
12/1/2015Michael GibertiniinsiderSell9,000$46.52$418,680.0036,282View SEC Filing  
11/2/2015Michael GibertiniinsiderSell9,000$41.70$375,300.0036,282View SEC Filing  
9/28/2015Alistair MacdonaldCOOSell44,522$39.93$1,777,763.4655,681View SEC Filing  
9/14/2015Gregory S. RushCFOSell32,426$45.06$1,461,115.568,132View SEC Filing  
8/31/2015Christopher L. GaenzleCAOSell17,421$41.16$717,048.367,291View SEC Filing  
8/31/2015James T OgleDirectorSell55,000$41.12$2,261,600.00183,386View SEC Filing  
8/17/2015Avista Capital Partners Ii Gp,Major ShareholderSell4,029,168$44.00$177,283,392.00View SEC Filing  
8/17/2015Teachers Pension Plan OntarioDirectorSell3,857,525$44.00$169,731,100.00View SEC Filing  
8/12/2015D. Jamie MacdonaldCEOSell57,021$44.00$2,508,924.00View SEC Filing  
8/12/2015Robert W BreckonDirectorSell8,381$44.00$368,764.00View SEC Filing  
5/14/2015Avista Capital Partners Ii Gp,Major ShareholderSell6,599,761$29.68$195,880,906.48View SEC Filing  
5/14/2015Teachers Pension Plan OntarioDirectorSell6,318,607$29.68$187,536,255.76View SEC Filing  
5/7/2015Gregory S RushCFOSell12,455$29.68$369,664.40View SEC Filing  
5/7/2015Michael GibertiniInsiderSell50,000$29.68$1,484,000.00View SEC Filing  
5/7/2015Robert W BreckonDirectorSell8,226$29.68$244,147.68View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Syneos Health (NASDAQ SYNH) News Headlines

Source:
DateHeadline
Does Syneos Health Inc (NASDAQ:SYNH) Go Up With The Market?Does Syneos Health Inc (NASDAQ:SYNH) Go Up With The Market?
finance.yahoo.com - April 21 at 9:03 AM
Syneos Health (SYNH) Now Covered by Analysts at Mitsubishi UFJ Financial GroupSyneos Health (SYNH) Now Covered by Analysts at Mitsubishi UFJ Financial Group
www.americanbankingnews.com - April 20 at 10:24 AM
Syneos Health Schedules First Quarter 2018 Earnings Call for Wednesday, May 9 ...Syneos Health Schedules First Quarter 2018 Earnings Call for Wednesday, May 9 ...
globenewswire.com - April 18 at 9:14 AM
Syneos Health Schedules First Quarter 2018 Earnings Call for Wednesday, May 9, 2018Syneos Health Schedules First Quarter 2018 Earnings Call for Wednesday, May 9, 2018
finance.yahoo.com - April 17 at 5:07 PM
Syneos Health (SYNH) Rating Lowered to Buy at BidaskClubSyneos Health (SYNH) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - April 16 at 5:55 PM
Syneos Health (SYNH) Downgraded to C at TheStreetSyneos Health (SYNH) Downgraded to C at TheStreet
www.americanbankingnews.com - April 14 at 4:13 PM
$770.78 Million in Sales Expected for Syneos Health Inc (SYNH) This Quarter$770.78 Million in Sales Expected for Syneos Health Inc (SYNH) This Quarter
www.americanbankingnews.com - April 14 at 1:47 AM
Syneos Health (SYNH) Stock Rating Reaffirmed by Goldman SachsSyneos Health (SYNH) Stock Rating Reaffirmed by Goldman Sachs
www.americanbankingnews.com - April 12 at 11:52 PM
Zacks: Brokerages Anticipate Syneos Health Inc (SYNH) to Announce $0.53 EPSZacks: Brokerages Anticipate Syneos Health Inc (SYNH) to Announce $0.53 EPS
www.americanbankingnews.com - April 12 at 11:14 PM
Critical Analysis: Syneos Health (SYNH) and Anavex Life Sciences (AVXL)Critical Analysis: Syneos Health (SYNH) and Anavex Life Sciences (AVXL)
www.americanbankingnews.com - April 12 at 11:35 AM
Syneos Health Inc (SYNH) Receives Average Rating of "Buy" from BrokeragesSyneos Health Inc (SYNH) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 11 at 7:35 PM
TBJ Data Dance: Inside the Triangle M&A listTBJ Data Dance: Inside the Triangle M&A list
www.bizjournals.com - April 8 at 5:03 PM
Syneos Health (SYNH) Rating Lowered to Hold at Zacks Investment ResearchSyneos Health (SYNH) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 7 at 11:36 PM
Syneos Health (SYNH) Stock Rating Reaffirmed by Robert W. BairdSyneos Health (SYNH) Stock Rating Reaffirmed by Robert W. Baird
www.americanbankingnews.com - April 7 at 9:54 PM
Syneos Health (SYNH) Rating Increased to Buy at Jefferies GroupSyneos Health (SYNH) Rating Increased to Buy at Jefferies Group
www.americanbankingnews.com - April 7 at 8:50 PM
Syneos Health (SYNH) Stock Rating Lowered by ValuEngineSyneos Health (SYNH) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 2 at 11:25 PM
Syneos Health (SYNH) Lifted to B- at TheStreetSyneos Health (SYNH) Lifted to B- at TheStreet
www.americanbankingnews.com - April 1 at 11:24 AM
Syneos Health (SYNH) Rating Increased to Buy at BidaskClubSyneos Health (SYNH) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - March 30 at 10:36 PM
Syneos Health Inc (NASDAQ:SYNH): Time For A Financial Health CheckSyneos Health Inc (NASDAQ:SYNH): Time For A Financial Health Check
finance.yahoo.com - March 28 at 4:38 PM
Syneos Health Inc (SYNH) Expected to Announce Quarterly Sales of $767.82 MillionSyneos Health Inc (SYNH) Expected to Announce Quarterly Sales of $767.82 Million
www.americanbankingnews.com - March 28 at 9:15 AM
Syneos Health Helps Establish New Industry Standards Group to Improve Clinical Trial Collaboration and ExecutionSyneos Health Helps Establish New Industry Standards Group to Improve Clinical Trial Collaboration and Execution
finance.yahoo.com - March 27 at 9:35 AM
$0.53 Earnings Per Share Expected for Syneos Health Inc (SYNH) This Quarter$0.53 Earnings Per Share Expected for Syneos Health Inc (SYNH) This Quarter
www.americanbankingnews.com - March 26 at 11:06 PM
Syneos Health (SYNH) and Capital Senior Living (CSU) Head to Head SurveySyneos Health (SYNH) and Capital Senior Living (CSU) Head to Head Survey
www.americanbankingnews.com - March 26 at 11:18 AM
Syneos Health Inc (SYNH) Receives Consensus Rating of "Buy" from BrokeragesSyneos Health Inc (SYNH) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 17 at 7:38 PM
Syneos Health (SYNH) Stock Rating Lowered by Zacks Investment ResearchSyneos Health (SYNH) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 14 at 10:52 AM
Zacks: Brokerages Anticipate Syneos Health Inc (SYNH) to Post $0.53 Earnings Per ShareZacks: Brokerages Anticipate Syneos Health Inc (SYNH) to Post $0.53 Earnings Per Share
www.americanbankingnews.com - March 9 at 5:18 PM
Syneos Health, Inc. (SYNH) Tops Q4 EPS by 14c, Offers Guidance - StreetInsider.comSyneos Health, Inc. (SYNH) Tops Q4 EPS by 14c, Offers Guidance - StreetInsider.com
www.streetinsider.com - March 2 at 5:20 PM
Syneos Health Reports Fourth Quarter and Full Year 2017 Results - GlobeNewswire (press release)Syneos Health Reports Fourth Quarter and Full Year 2017 Results - GlobeNewswire (press release)
globenewswire.com - March 2 at 5:20 PM
Syneos Health (SYNH) Given "Equal Weight" Rating at BarclaysSyneos Health (SYNH) Given "Equal Weight" Rating at Barclays
www.americanbankingnews.com - March 1 at 6:36 PM
Syneos Health (SYNH) Price Target Raised to $55.00 at SunTrust BanksSyneos Health (SYNH) Price Target Raised to $55.00 at SunTrust Banks
www.americanbankingnews.com - March 1 at 12:54 PM
Syneos Health, Inc. (SYNH) Tops Q4 EPS by 14c, Offers GuidanceSyneos Health, Inc. (SYNH) Tops Q4 EPS by 14c, Offers Guidance
www.streetinsider.com - March 1 at 8:57 AM
Should You Buy Syneos Health Inc (NASDAQ:SYNH) Now?Should You Buy Syneos Health Inc (NASDAQ:SYNH) Now?
finance.yahoo.com - March 1 at 8:57 AM
Syneos Health (SYNH) Releases Q1 Earnings GuidanceSyneos Health (SYNH) Releases Q1 Earnings Guidance
www.americanbankingnews.com - February 28 at 9:14 AM
Syneos Health (SYNH) Issues FY18 Earnings GuidanceSyneos Health (SYNH) Issues FY18 Earnings Guidance
www.americanbankingnews.com - February 28 at 9:14 AM
Syneos Health Reports Fourth Quarter and Full Year 2017 ResultsSyneos Health Reports Fourth Quarter and Full Year 2017 Results
finance.yahoo.com - February 28 at 9:08 AM
Syneos Health (SYNH) Price Target Cut to $46.00Syneos Health (SYNH) Price Target Cut to $46.00
www.americanbankingnews.com - February 26 at 1:30 PM
Syneos Health (SYNH) Upgraded to "Outperform" at Wells Fargo & CoSyneos Health (SYNH) Upgraded to "Outperform" at Wells Fargo & Co
www.americanbankingnews.com - February 24 at 3:50 PM
Robert W. Baird Reiterates $50.00 Price Target for Syneos Health (SYNH)Robert W. Baird Reiterates $50.00 Price Target for Syneos Health (SYNH)
www.americanbankingnews.com - February 23 at 2:30 PM
Management turnover pressures Syneos Health, down 15%Management turnover pressures Syneos Health, down 15%
seekingalpha.com - February 22 at 5:01 PM
Zacks: Analysts Anticipate Syneos Health Inc (SYNH) to Announce $0.56 EPSZacks: Analysts Anticipate Syneos Health Inc (SYNH) to Announce $0.56 EPS
www.americanbankingnews.com - February 21 at 1:28 AM
Syneos Health (SYNH) Scheduled to Post Quarterly Earnings on MondaySyneos Health (SYNH) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - February 19 at 4:30 AM
Q2 Holdings Inc (NYSE:QTWO): Financial Strength AnalysisQ2 Holdings Inc (NYSE:QTWO): Financial Strength Analysis
finance.yahoo.com - February 14 at 9:21 AM
INC Research (SYNH) Raised to Buy at Zacks Investment ResearchINC Research (SYNH) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - February 13 at 11:50 AM
A Good Quarter and an Earnings Beat: Why Is Canada Goose Holdings Inc. Down?A Good Quarter and an Earnings Beat: Why Is Canada Goose Holdings Inc. Down?
www.msn.com - February 12 at 9:18 AM
INC Research (SYNH) & Its Rivals Financial AnalysisINC Research (SYNH) & Its Rivals Financial Analysis
www.americanbankingnews.com - February 11 at 3:21 PM
Syneos Health Names Lisa van Capelle Chief Human Resources OfficerSyneos Health Names Lisa van Capelle Chief Human Resources Officer
finance.yahoo.com - February 8 at 4:14 PM
Analyzing INC Research (SYNH) & Its CompetitorsAnalyzing INC Research (SYNH) & Its Competitors
www.americanbankingnews.com - February 7 at 9:52 AM
Head-To-Head Review: INC Research (SYNH) and The CompetitionHead-To-Head Review: INC Research (SYNH) and The Competition
www.americanbankingnews.com - February 6 at 1:28 PM
INC Research Holdings Inc (SYNH) Expected to Announce Quarterly Sales of $756.76 MillionINC Research Holdings Inc (SYNH) Expected to Announce Quarterly Sales of $756.76 Million
www.americanbankingnews.com - February 6 at 11:28 AM
When It Comes to Artificial Intelligence in Healthcare, Patients Fear the Replacement of Doctors, Yet Are Open to AI Nurse SupportWhen It Comes to Artificial Intelligence in Healthcare, Patients Fear the Replacement of Doctors, Yet Are Open to AI Nurse Support
finance.yahoo.com - February 6 at 9:18 AM

SEC Filings

Syneos Health (NASDAQ:SYNH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Syneos Health (NASDAQ:SYNH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Syneos Health (NASDAQ SYNH) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.